SATB-1 and Her2 as predictive molecular and immunohistochemical markers for urothelial cell carcinoma of the bladder

Hussein, Samia; Fathi, Anan; Abouhashem, Nehal S.; Amer, Samar A.; Hemeda, Mohamed; Mosaad, Hala

doi:10.3233/cbm-200072

Cited by 11 publications

(7 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to our study, a significant difference was observed in the percentage of HER2+ among different clinical stages of UC ( p = 0.019) ( Table 2 ). This finding is consistent with another research study, which demonstrated a strong association between elevated levels of HER2 and the stage of UC at both mRNA and protein levels ( p < 0.001) ( Hussein et al, 2021 ). It is worth noting that HER2 overexpression is considered an early event in urothelial tumor development and rarely occurs during subsequent tumor progression.…”

Section: Discussionsupporting

confidence: 93%

Expression of HER2 in high-grade urothelial carcinoma based on Chinese expert consensus and the clinical effects of disitamab vedotin-tislelizumab combination therapy in the treatment of advanced patients

Zhu,

Chang,

Zhao

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Background: A vast number of researchers have discovered high levels of human epidermal growth factor receptor-2 (HER2) expression in urothelial carcinoma (UC), but they do not use a uniform scoring system. Based on the 2021 edition of clinical pathological expert consensus on HER-2 testing in UC in China, we investigated the expression level and clinical significance of HER2 in high-grade UC. Furthermore, we looked at the prognosis of patients with locally advanced/metastatic UC after combining HER2 targeting antibody-drug conjugates (ADC) medication disitamab vedotin (DV) with programmed cell death protein 1 (PD-1) inhibitor tislelizumab.Patients and methods: From 2019 to 2022, we collected paraffin specimens of UC from the Department of Urology at the Provincial Hospital Affiliated to Shandong First Medical University. HER2 expression-related factors were investigated. Patients with advanced UC who have failed systemic chemotherapy at least once and had received immune checkpoint inhibitor (ICI) medication during second-line treatment were selected and treated with DV in combination with tislelizumab. We assessed the therapy’s efficacy and safety.Results: 185 patients with high-grade UC were included in this investigation. 127 patients (68.7%) were HER2 positive (IHC 2+/3+) according to the 2021 Clinical pathological expert consensus on HER2 testing in UC in China. The clinical stage of UC differed statistically significantly between the HER2-and HER2+ groups (p = 0.019). Sixteen advanced UC patients were treated with DV and tislelizumab for a median of 14 months. The disease control rate was 87.5%, while the objective response rate (ORR) was 62.5%. The ORR of HER2+ individuals was higher than that of HER2-individuals (70.0% vs. 50.0%). The median progression-free survival or overall survival was not reached. In this study, the incidence of treatment-related adverse events was 68.8% (11/16), with all of them being grade 1 or 2 adverse reactions.Conclusion: HER2 protein expressed at a high percentage in UC, and 68.7% patients expressed HER2 positive (IHC 2+/3+). HER2+ expression is positively correlated with higher clinical stage of UC. HER2 targeted ADC drug disitamab vedotin combining with PD-1 inhibitor tislelizumab has shown efficacy, safety and controllable adverse reactions in the treatment of advanced UC.

show abstract

Section: Discussionsupporting

confidence: 93%

Expression of HER2 in high-grade urothelial carcinoma based on Chinese expert consensus and the clinical effects of disitamab vedotin-tislelizumab combination therapy in the treatment of advanced patients

Zhu,

Chang,

Zhao

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…BCa expresses multiple tumor-associated antigens, suggesting favorable conditions for CAR T cell therapy. Many pan-cancer tumor targets, including human epidermal growth factor receptor 2 (HER2), mucin 1 (MUC1), and EGFR, are also expressed at high levels in UCs and may serve as therapeutic targets [50,51]. One current ongoing clinical trial targets HER2 (NCT03740256).…”

Section: Car T Cell Therapy In Bcamentioning

confidence: 99%

Molecular understanding and clinical outcomes of CAR T cell therapy in the treatment of urological tumors

Zhang,

Wang,

et al. 2024

Cell Death Dis

View full text Add to dashboard Cite

Chimeric antigen receptor engineered T (CAR T) cell therapy has developed rapidly in recent years, leading to profound developments in oncology, especially for hematologic malignancies. However, given the pressure of immunosuppressive tumor microenvironments, antigen escape, and diverse other factors, its application in solid tumors is less developed. Urinary system tumors are relatively common, accounting for approximately 24% of all new cancers in the United States. CAR T cells have great potential for urinary system tumors. This review summarizes the latest developments of CAR T cell therapy in urinary system tumors, including kidney cancer, bladder cancer, and prostate cancer, and also outlines the various CAR T cell generations and their pathways and targets that have been developed thus far. Finally, the current advantages, problems, and side effects of CAR T cell therapy are discussed in depth, and potential future developments are proposed in view of current shortcomings.

show abstract

“…Elevated mRNA and protein levels of both genes were significantly associated with tumor stage and lymph node involvement. These findings suggest that SATB1 and ERBB2 may serve as potential biomarkers for predicting the aggressive behavior and poor prognosis of bladder cancer [ 101 ]. In NMIBC tissues, both the mRNA and protein expression of SATB1 was significantly upregulated as compared to that of adjacent normal tissues.…”

Section: Homeobox Genes In Bladder Cancermentioning

confidence: 99%

Homeobox Gene Expression Dysregulation as Potential Diagnostic and Prognostic Biomarkers in Bladder Cancer

2023

View full text Add to dashboard Cite

Homeobox genes serve as master regulatory transcription factors that regulate gene expression during embryogenesis. A homeobox gene may have either tumor-promoting or tumor-suppressive properties depending on the specific organ or cell lineage where it is expressed. The dysregulation of homeobox genes has been reported in various human cancers, including bladder cancer. The dysregulated expression of homeobox genes has been associated with bladder cancer clinical outcomes. Although bladder cancer has high risk of tumor recurrence and progression, it is highly challenging for clinicians to accurately predict the risk of tumor recurrence and progression at the initial point of diagnosis. Cystoscopy is the routine surveillance method used to detect tumor recurrence. However, the procedure causes significant discomfort and pain that results in poor surveillance follow-up amongst patients. Therefore, the development of reliable non-invasive biomarkers for the early detection and monitoring of bladder cancer is crucial. This review provides a comprehensive overview of the diagnostic and prognostic potential of homeobox gene expression dysregulation in bladder cancer.

show abstract

SATB-1 and Her2 as predictive molecular and immunohistochemical markers for urothelial cell carcinoma of the bladder

Cited by 11 publications

References 31 publications

Expression of HER2 in high-grade urothelial carcinoma based on Chinese expert consensus and the clinical effects of disitamab vedotin-tislelizumab combination therapy in the treatment of advanced patients

Expression of HER2 in high-grade urothelial carcinoma based on Chinese expert consensus and the clinical effects of disitamab vedotin-tislelizumab combination therapy in the treatment of advanced patients

Molecular understanding and clinical outcomes of CAR T cell therapy in the treatment of urological tumors

Homeobox Gene Expression Dysregulation as Potential Diagnostic and Prognostic Biomarkers in Bladder Cancer

Contact Info

Product

Resources

About